An update on new anticoagulants

Current Drug Targets - Cardiovascular and Haematological Disorders

Volumn 3, Issue 4, 2003, Pages 287-300

  Linkins, Lori Ann ^a   Weitz, Jeffrey I ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; ABCIXIMAB; ACETYLSALICYLIC ACID; ACTIVATED PROTEIN C; ALTEPLASE; ANTICOAGULANT AGENT; ANTIVITAMIN K; ARGATROBAN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING INHIBITOR; CLOPIDOGREL; DALTEPARIN; DROTRECOGIN; ENOXAPARIN; EPTIFIBATIDE; FONDAPARINUX; HEPARIN; HIRUDIN; HIRULOG; IDRAPARINUX; MELAGATRAN; RAZAXABAN; RECOMBINANT NEMATODE ANTICOAGULANT PEPTIDE; RECOMBINANT THROMBOMODULIN; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN; XIMELAGATRAN;

ANTICOAGULATION; ARTERY THROMBOSIS; BLEEDING; BLOOD VESSEL INJURY; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; HUMAN; LIVER DYSFUNCTION; LIVER METABOLISM; REVIEW; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOGENESIS; URINARY EXCRETION; VEIN THROMBOSIS;

ANTICOAGULANTS; HUMANS; THROMBOEMBOLISM;

EID: 0348110433     PISSN: 15680061     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568006033481366     Document Type: Review

References (83)

1. Hirsh, J., Warkentin, T.E., Shaugnessy, S.G, Anand, S.S., Halperin, J.L., Raschke, R., Granger, C., Ohman, E.M., Dalen, J.E. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy and safety. Chest. 2001, 119, 64S-94S.
2. Hirsh, J., Dalen, J.E., Anderson, D.R., Poller, L., Bussey, H., Ansell, J., Deykin, D. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001,119, 8S-21S.
3. Fuster, V., Badimon, L., Badimon, J.J., Chesebro, J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes. N. Engl. J. Med. 1992, 326, 310-318.
4. Furie, B., Furie, B.C. Molecular and cellular biology of blood coagulation. N. Engl. J. Med. 1992, 326, 800-806.
5. Broze, G.J. Jr. Tissue factor pathway inhibitor. Thromb. Haemost. 1995, 74, 90-93.
6. Walsh, P.N. Roles of platelets and factor XI in the initiation of blood coagulation by thrombin. Thromb. Haemost. 2001, 86, 75-82.
7. Esmon, C.T., Ding, W., Yasuhiro, K., Gu, J.M., Ferrell, G., Regan, L.M., Stearns-Kurosawa, D.J., Kurosawa, S., Mather, T., Laszik, Z., Esmon, N.L. The protein C pathway: new insights. Thromb. Haemost. 1997, 78, 70-74.
8. Abraham, E., Reinhart, K., Svoboda, P., Seibert, A., Olthoff ,D., Dal Nogare, A., Postier, R., Hempelmann, G., Butler, T., Martin, E., Zwingelstein, C., Percell, S., Shu, V., Leighton, A., Creasey, A.A. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit. Care. Med. 2001, 29, 2081-9.
9. Bernard, G,R., Vincent, J.L., Laterre, P.F., LaRosa, S.P., Dhainaut, J.F., Lopez-Rodriguez, A., Steingrub, J.S., Garber, G.E., Helterbrand, J.D., Ely, E.W., Fisher, C.J. Jr. PROWESS Study Group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 2001, 344, 699-709.
10. Abraham, E., Reinhart, K., Opal, S. for the OPTIMIST Trial Study Group. Efficacy and safety of tigacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003, 290, 238-247.
11. Cappello, M., Vlasuk, G.P., Bergum, P.W., Huang, S., Hotez, P.J. Ancylostoma caninum anticoagulant peptide: a hookworm-derived inhibitor of human coagulation factor Xa. Proc. Natl. Acad. Sci. USA 1995, 92,6152-6156.
12. Stassens, P., Bergum, P.W., Gansemans, Y., Jespers, L., Laroche, Y., Huang, S., Maki, S., Messens, J., Lauwereys, M., Cappello, M., Hotez, P.J., Lasters, I., Vlasuk, G.P. Anticoagulant repertoire of the hookworm Ancylostoma caninum. Proc. Natl. Sci. USA 1996, 93, 2149-2154.
13. Lee, A., Agnelli, G., Buller, H., Ginsberg, J., Heit, J., Rote, W., Vlasuk, G., Costantini, L., Julian, J., Comp, P., van Der Meer, J. Piovella, F., Raskob, G., Gent, M. Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation 2001, 104, 74-78.
14. Taylor, F.B. Jr. Role of tissue factor and factor VIIa in the coagulant and inflammatory response to LD100 Escherichia coli in the baboon. Haemostasis 1996, 26, 83-91.
15. Jang, Y., Guzman, L.A., Lincoff, A.M., Gottsauner-Wolf, M., Forudi, F., Hart, C.E., Courtman, D.W., Ezban, M., Ellis, S.G., Topol, E.J. Influence of blockade at specific levels of the coagulant cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation 1995, 92, 3041-3050.
16. Lincoff, A.M. First clinical investigation of a tissue-factor inhibitor administered during percutaneous coronary revascularization: a randomized, double-blinded, dose-escalation trial-assessing safety and efficacy of FFR-FVIIa in percutaneous transluminal coronary angioplasty (ASIS) trial. JACC 2000, 36, 312 (abstract).
17. Weitz, J.I., Crowther, M. Direct thrombin inhibitors. Thrombosis Research 2002, 106, V275-V284.
18. Boneu, B., Necciari, J., Cariou, R., Sie, P., Gabaig, A.M., Kieffer, G., Dickinson, J., Lamond, G., Moelker, H., Mant, T. Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/ORG31540) with high affinity to antithrombin III in man. Thromb. Haemost. 1995, 74, 1468-73.
19. Bijsterveld, N.R., Moons, A.H., Boekholdt, S.M., van Aken, B.E., Fennema, H., Peters, R.J., Meijers, J.C., Buller, H.R., Levi, M. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparniux in healthy volunteers. Circulation 2002, 106, 2550-4.
20. Friksson, B.I., Bauer, K.A., Lassen, M.R., Turpie, A.G. Steering Committee of the Pentasaccharide in Hip-Fracture Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N. Engl. J. Med. 2001, 345, 1298-304.
21. Lassen, M.R., Bauer, K.A., Eriksson, B.I., Turpie. European Pentasaccharide Elective Surgery Study (EPHESUS) Steering Committee. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 2002, 359, 1715-20.
22. Turpie, A.G., Bauer, K.A., Eriksson, B.I., Lassen, M.R. PENTATHALON 2000 Study Steering Committee. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002, 359, 1721-26.
23. Bauer, K.A., Eriksson, B.I., Lassen, M.R., Turpie, AG. Steering Committee of the Pentasaccharide in Major Knee Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N. Engl. J. Med. 2001, 345, 1305-10.
24. Eriksson, B.I., Bauer, K.A., Lassen, M.R., Turpie, A.G. Influence of the duration of fondaparinux (Arixtra) prophylaxis in preventing venous thromboembolism following major orthopedic surgery. J. Thromb. Haemost. 2003, 1, 383-4.
25. Matisse Investigators. Fondaparinux (Arixtra) in comparison to low-molecular weight heparin for the initial treatment of symptomatic deep venous thrombosis or pulmonary embolism - the Matisse clinical outcome studies. Blood 2002, 100, 302 (abstract).
26. Coussement, P.K., Bassand, J.P., Convens, C., Vrolix, M., Boland, J., Grollier, G., Michels, R., Vahanian, A., Vanderheyden, M., Rupprecht, H.J., Van de Werf, F. PENTALYSE Investigators. A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study. Eur. Heart J. 2001, 22, 1716-24.
27. Ferguson, J.J. Meeting highlights - American Heart Association scientific sessions 2001. Circulation 2002, 105, e37-e41.
28. Herbert, J.M., Herault, J.P., Bernat, A., van Amsterdam, R.G., Lormeau, J.C., Petitou ,M., Van Boeckel, C., Hoffmann, P., Meuleman, D.G. Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood 1998, 9, 4197-205.
29. Persist Investigators. A novel long-acting synthetic factor Xa inhibitor (idraparinux sodium) to replace warfarin for secondary prevention in deep vein thrombosis: a phase II evaluation. Blood 2002, 100, 301 (abstract).
30. Dyke, C.K., Becker, R.C., Kleiman, N.S., Hochman, J.S., Bovill, E.G., Lincoff, A.M., Gerstenblith, G., Dzavik, V., Gardner, L.H., Hasselblad, V., Zillman, L.A., Shimoto, Y., Robertson ,T.L., Kunitada, S., Armstrong, P.W., Harrington, R.A. First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation. Circulation 2002, 105, 2385-91.
31. Manns, B.J., Lee, H., Doig, C.J., Johnson, D., Donaldson, C. An economic evaluation of activated protein C treatment for severe sepsis. N. Eng. J. Med. 2002, 347, 993-1000.
32. Ettingshausen, C.E., Veldmann, A., Beeg, T., Schneider, W., Jager, G., Kreuz, W. Replacement therapy with protein C concentrate in infants and adolescents with meningococcal sepsis and purpura fulminans. Semin. Thromb. Hemost. 1999, 25, 537-41.
33. White, B., Livingstone, W., Murphy, C., Hodgson, A., Rafferty, M., Smith, O.P. An open-label study of tile role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. Blood 2000, 96,3719-24.
34. Faust, S.N., Levin, M., Harrison, O.B., Goldin, R.D., Lockhart, M.S., Kondaveeti, S., Laszik, Z., Esmon, C.T., Heyderman, R.S. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N. Engl. J. Med. 2001, 345, 408-16.
35. Maruyama, I. Recombinant thrombomodulin and activated protein C in the treatment of disseminated intravascular coagulation. Thromb. Haemost. 1999, 82, 718-21.
36. Kearon, C., Comp, C., Douketis, D., Royds, R., Yamada, K., Gent, M. A dose-response study of a recombinant human soluble thrombomodulin (ART-123) for prevention of venous thromboembolism after unilateral total hip replacement. J. Thromb. Haemost. 2003, Suppl 1,abstract OC330.
37. Wallis, R.B. Hirudins: from leeches to man. Semin. Thromb. Hemost. 1996, 22, 185-196.
38. Toschi, V., Lettino, M., Gallo, R., Badimon, J.J., Chesebro, J.H. Biochemistry and biology of hirudin. Coron. Artery Dis. 1996, 7, 420-428.
39. Lefevre, G., Duval, M., Gauron, S., Brookman, L.J., Rolan, P.E., Morris, T.M., Piraino, A.J., Morgan, J.M., Palmisano, M., Close, P. Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin. Clin. Pharmacol. Ther. 1997, 62, 50-59.
40. Anonymous. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischaemia without ST elevation: a pilot study. Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. Circulation 1997, 96, 769-77.
41. Anonymous. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Organization to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Lancet 1999, 353, 429-38.
42. Eriksson, B.I., Ekman, S., Lindbratt, S., Baur, M., Bach, D., Torholm, C., Kalebo, P., Close, P. Prevention of thromboembolism with use of recombinant hitudin. Results of a double- blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement. J. Bone Jt.Surg-Am. Vol. 1997, 79, 326-33.
43. Eriksson, B.I., Wille-Jorgensen, P., Kalebo, P., Mouret, P., Rosencher, N., Bosch, P., Baur, M., Ekman, S., Bach, D., Lindbratt, S., Close, P. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N. Engl. J. Med. 1997, 337, 1329-35.
44. Schiele, F., Lindgaerde, F., Friksson, H., Bassand, J.P., Wallmark, A., Hansson, P.O., Grollier, G., Sjo, M., Moia, M., Camez, A., Smyth, V., Walker, M. Subcutaneous recombinant hirudin (HBW 023) versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicentre prospective dose-ranging randomized trial. International Multicentre Hirudin Study Group. Thromb. Haemost. 1997, 77, 834-8.
45. Maraganore, J.M., Bourdon, P., Jablonski, J., Ramachandran, K.L., Fenton, J.W. II. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. J. Clin. Invest. 1990, 29, 7095-101.
46. Skrzypczak-Jankun, E., Carperos, V.E., Ravichandran, K.L., Tulinsky, A., Westbrook, M., Maraganore, J.M. Structure of the hirugen and hirulog 1 complexes of alpha-thrombin. J. Mol. Biol. 1991, 221, 1379-93.
47. Witting, J.I., Bourdon, P., Maraganore, J.M., Fenton, J.W. II. Hirulog-1 and -B2 thrombin specificity. Biochem, J. 1992, 287, 663-4.
48. Fox, I., Dawson, A., Loynds, P., Eisner, J., Findlen, K., Levin, E., Hanson, D., Mant, T., Wagner, J., Maraganore, J. Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans. Thromb. Haemost. 1993, 69, 157-63.
49. Robson, R. The use of bivalirudin in patients with renal impairment. J. Invasive. Cardiol. 2000, 12, 33F-6F.
50. Bittl, J.A., Strony, J., Brinker, J.A., Ahmed, W.H., Meckel, C.R., Chaitman, B.R., Maraganore, J., Deutsch, E., Adelman, B. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or post infarction angina. Hirulog Angioplasty Study Investigators. N. Engl. J.Med. 1995, 333, 764-9.
51. Bittl, J.A., Chaitman, B.R., Feit, F., Kimball, W., Topol, E.J. Bivalirudin versus heparin during coronary angioplasty for unstable or post-infarction angina: the final report of the Bivalirudin Angioplasty Study. Am. Heart. J. 2001, 142, 952-959.
52. Lincoff, A.M., Kleiman, N.S., Kottke-Marchant, K., Maierson, E.S., Maresh, K., Wolski, K.E., Topol, E.J. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am. Heart J. 2002, 143, 847-53.
53. Lincoff, A.M. The REPLACE-2 Trial: Bivalirudin and provisional GP IIb/IIIa blockade compared with heparin and planned GP IIb/IIIa blockade during percutaneous coronary intervention. Circulation 2002, 106, 2986-a.
54. Hursting, M.J., Alford, K.L., Becker, J.C., Brooks, R.L., Joffrion, J.L., Knappenberger, G.D., Kogan, P.W., Kogan, T.P., McKinney, A.A., Schwarz, R.P. Jr. Novastan (brand of argatroban): a small-molecule, direct thrombin inhibitor. Semin. Thromb. Haemost. 1997, 23, 503-16.
55. Banner, D.W., Hadvary, P. Inhibitor binding to thrombin: x-ray crystallographic studies. Adv. Exp. Med. Biol. 1993, 340, 27-33.
56. Swan, S.K., Hursting, M.J. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000, 20, 318-29.
57. Gustafsson, D., Nystrom, J.E., Carlsson, S., Bredberg, U., Eriksson, U., Gyzander, E., Elg, M., Antonsson, T., Hoffman, K., Ungell, A., Sorensen, H., Nagard, S., Abrahamsson, A., Bylund, R. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb. Res. 2001, 101, 171-81.
58. Eriksson, B.I., Bergqvist, D., Kalebo, P., Dahl, O.E., Lindbratt, S., Bylock, A., Frison, L., Eriksson, U.G., Welin, L., Gustafsson, D. Melagatran for Thrombin inhibition in Orthopaedic Surgery. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 2002, 360, 1441-47.
59. Eriksson, B.I., Agnelli, G., Cohen, A.T., Dahl, O.E., Mouret, P., Rosencher, N., Eskilson, C., Nylander, I., Frison, L., Ogren, M. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee joint replacement. Thromb. Haemost. 2003, 89, 288-96.
60. Glynn, O. The EXPRESS study: preliminary results. Int. J. Clin. Pract. 2003, 57, 57-59.
61. Colwell, C.W., Berkowitz, S.D., Davidson, B.L., Lotke, P.A., Ginsberg, J.S., Lieberman, J.R., Neubauer, J., Whipple J/P/, Peters, G.R., Francis, C.W. Randomized, double-blind, comparison of ximelagatran, an oral direct thrombin inhibitor, and enoxaparin to prevent venous thromboembolism after total hip arthroplasty. Blood 2001, 98, 2952 (abstract).
62. Francis, C.W., Davidson, B.L., Berkowitz, S.D., Lotke, P.A., Ginsberg, J.S., Lieberman, J.R., Webster, A.K., Whipple, J.R., Peters, G.R., Colwell, C.W. Jr. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. Ann. Intern. Med. 2002, 137, 648-655.
63. Francis, C.W., Berkowitz, S.D., Comp, P.C., Lieberman, J.R., Ginsberg,J.S., Paiement, G., Peters, G.R., Roth, A.W., Colwell, C.W. Jr., Randomized, double-blind, comparison of ximelagatran, an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism after total knee replacement. Blood 2002, 100, 300 (abstract).
64. Eriksson, H., Wahlander, K., Gustafsson, D., Welin, L.T., Frison, L., Schulman, S. For the THRIVE Investigators. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE 1. J. Thromb. Haemost. 2003, 1, 41-47.
65. Huisman, M.V. THRIVE II&V Investigators. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current standard therapy for acute symptomatic deep vein thrombosis, with or without pulmonary embolism: a randomized, double-blind, multinational study. J. Thromb. Haemost. 2003, Suppl 1, abstract OC003.
66. Eriksson, H., Wahlander, K., Lundstrom, T., Billing, Clason, S., Schulman, S., for the THRIVE III Investigators. Extended secondary prevention with the oral direct thrombin inhibitor ximelagatran for 18 months after 6 months of anticoagulation in patients with venous thromboembolism: a randomized, placebo-controlled trial. Blood 2002, 100, 297 (abstract).
67. Wallentin, L., Wilcox, R., Weaver, D., Emanuelsson, H., Goodvin, A., Nystrom, P., Bylock, A. For the ESTEEM Investigators. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 2003, 362, 789-797.
68. Petersen, P., Grind, M., Adler, J. SPORTIF II Investigators. Ximelagatran versus warfarin for stroke prevention in patients with non-valvular atrial fibrillation SPORTIF II: a dose-guiding, tolerability, and safety study. J. Am. Coll. Cardiol. 2003, 41, 1445-51.
69. Petersen, P. A long-term follow-up of ximelagatran as an oral anticoagulant for the prevention of stroke and systemic embolism in patients with atrial fibrillation. Blood 2001, 98, 2953 (abstract).
70. Halperin, J.L. Ximelagatran compared with warfarin for the prevention of stroke and systemic embolic events in patients with nonvalvular atrial fibrillation: rationale, objectives, design and organization of two long-term clinical trials (SPORTIF III & V). Blood 2002, 100, 3976 (abstract).
71. Halperin, J.L. SPORTIF-III: A long-term randomized trial comparing ximelagatran with warfarin for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Presentation at American College of Cardiology 2003.
72. Daud, A.N., Ahsan, A., Iqbal, O., Walenga, J.M., Silver, P.J., Ahmad, S., Fareed, J. Synthetic heparin pentasaccharide depolymerization by heparinase I: molecular and biological implications. Clin. Appl. Thromb. Hemost. 2001, 7, 58-64.
73. Prandoni, P., Bruchi, O., Sabbion, P., Tanduo, C., Scudeller, A., Sardella, C., Errigo, B., Pietrobelli, F., Maso, G., Girolami, A. Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study. Arch. Intern. Med. 2002, 162, 1966-71.
74. Hull, R.D., Pineo, G.F., Francis, C., Bergqvist, D., Fellenius, C., Soderberg, K., Holmqvist, A., Mant, M., Dear, R., Baylis, B., Mah, A., Brant, R. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators. Arch. Intern. Med. 2000, 160, 2208-15.
75. Cohen, A.T., Bailey, C.S., Alikhan, F., Cooper, D.J. Extended thromboprophylaxis with low molecular weight heparin reduces symptomatic venous thromboembolism following lower limb arthroplasty - a meta-analysis. Thromb. Haemost. 2001, 85, 940-1.
76. Levine, M.N., Hirsh, J., Gent, M., Turpie, A.G., Weitz, J., Ginsberg, J., Geerts, W., LeClerc, J., Neemeh, J., Powers, P. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb. Haemost. 1995, 74, 606-11.
77. Schulman, S., Rhedin, A.S., Lindmarker, P., Carlsson, A., Larfars, G., Nicol, P., Loogna, E., Svensson, E., Ljungberg, B., Walter, H. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N. Engl. J. Med. 1995, 332, 1661-5.
78. Schulman, S., Granqvist, S., Holmstrom, M., Carlsson, A., Lindmarker, P., Nicol. P., Eklund, S.G., Nordlander, S., Larfars, G., Leijd, B., Linder, O., Loogna, E. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N. Engl. J. Med. 1997, 336, 393-8.
79. Keaton, C., Gent, M., Hirsh, J., Weitz, J., Kovacs, M.J., Anderson, D.R., Turpi, A.G., Green. D., Ginsberg, J.S., Wells. P., MacKinnon, B., Julian. J.A. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N. Engl. J. Med. 1999, 340, 901-7.
80. Agnelli, G., Prandoni, P., Santamaria, M.G., Bagatella, P., Iorio, A., Bazzan, M., Moia, M., Guazzaloca, G., Bertoldi, A., Tomasi, C., Scannapieco, G., Ageno, W. Warfarin Optimal Duration Italian Trial Investigators. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N. Engl. J. Med. 2001, 345, 165-9.
81. Albers, G.W., Dalen, J., Laupacis, A., Manning, W.J., Petersen, P., Singer, D.E. Antithrombotic therapy in atrial fibrillation. Chest 2001, 119, 194S-206S.
82. Yusuf, S., Zhao, F., Mehta, S.R., Chrolavicius, S., Tognoni, G., Fox, K.K. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 2001, 345, 494-502.
83. Hurlen, M.H., Abdelnoor, M., Smith, P., Erikssen, J., Arnesen, H. Warfarin, aspirin, or both after myocardial infarction. N. Engl. J. Med. 2002, 347, 969-74.